Display options
Cite
Gomes-Lima CJ, Wu D, Rao SN, et al. Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes. J Endocr Soc. 2018;3(2):359-371doi: 10.1210/js.2018-00241.
Gomes-Lima, C. J., Wu, D., Rao, S. N., Punukollu, S., Hritani, R., Zeymo, A., Deeb, H., Mete, M., Aulisi, E. F., Van Nostrand, D., Jonklaas, J., Wartofsky, L., & Burman, K. D. (2019). Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes. Journal of the Endocrine Society, 3(2), 359-371. https://doi.org/10.1210/js.2018-00241
Gomes-Lima, Cristiane J, et al. "Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes." Journal of the Endocrine Society vol. 3,2 (2019): 359-371. doi: https://doi.org/10.1210/js.2018-00241
Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, Zeymo A, Deeb H, Mete M, Aulisi EF, Van Nostrand D, Jonklaas J, Wartofsky L, Burman KD. Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes. J Endocr Soc. 2018 Nov 21;3(2):359-371. doi: 10.1210/js.2018-00241. eCollection 2019 Feb 01. PMID: 30706042; PMCID: PMC6348752.
Copy Download .nbib Format: NLM
Share it on

J Endocr Soc. 2018 Nov 21;3(2):359-371. doi: 10.1210/js.2018-00241. eCollection 2019 Feb 01.

Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes.

Journal of the Endocrine Society

Cristiane J Gomes-Lima, Di Wu, Sarika N Rao, Sree Punukollu, Rama Hritani, Alexander Zeymo, Hala Deeb, Mihriye Mete, Edward F Aulisi, Douglas Van Nostrand, Jacqueline Jonklaas, Leonard Wartofsky, Kenneth D Burman

Affiliations

  1. MedStar Clinical Research Center, MedStar Health Research Institute, Washington, District of Columbia.
  2. Section of Endocrinology, MedStar Washington Hospital Center, Washington, District of Columbia.
  3. Nuclear Medicine Research, MedStar Washington Hospital Center, Washington, District of Columbia.
  4. Division of Endocrinology, Department of Medicine, Georgetown University, Washington, District of Columbia.
  5. Resident Internal Medicine - MedStar Washington Hospital Center, Washington, District of Columbia.
  6. Department of Biostatistics and Biomedical Informatics, MedStar Health Research Institute, Washington, District of Columbia.
  7. Department of Neurosurgery, MedStar Washington Hospital Center, Washington, District of Columbia.

PMID: 30706042 PMCID: PMC6348752 DOI: 10.1210/js.2018-00241

Abstract

BACKGROUND AND OBJECTIVE: The brain is an unusual site for distant metastases of differentiated thyroid carcinoma (DTC). The aim of this study was to document the prevalence of brain metastases from DTC at our institutions and to analyze the current therapies and the outcomes of these patients.

METHODS: We performed a retrospective chart review of patients with DTC and secondary neoplasia of the brain.

RESULTS: From 2002 to 2016, 9514 cases of thyroid cancer were evaluated across our institutions and 24 patients met our inclusion criteria, corresponding to a prevalence of 0.3% of patients with DTC. Fourteen (58.3%) were female and 10 (41.7%) were male. Fifteen patients had papillary thyroid cancer (PTC) (62.5%). Brain metastases were diagnosed 0 to 37 years (mean ± SD, 10.6 ± 10.4 years) after the initial diagnosis of thyroid cancer. Patients undergoing surgery had a median survival time longer than those that did not undergo surgery (27.3 months vs 6.8 months;

CONCLUSION: The prevalence of brain metastases of DTC in our institutions was 0.3% over 15 years. The median survival time after diagnosis of brain metastases was 19 months. In our study population, the use of TKI improved the survival rates.

Keywords: DTC; brain metastases; prevalence; therapies; thyroid cancer

References

  1. Ann Nucl Med. 2000 Apr;14(2):111-4 - PubMed
  2. Kaku Igaku. 2000 Jul;37(4):349-57 - PubMed
  3. J Neurooncol. 2001 Jan;51(1):33-40 - PubMed
  4. Neurosurgery. 2001 Oct;49(4):1008-13 - PubMed
  5. Cancer. 2003 Jul 15;98(2):356-62 - PubMed
  6. J Clin Oncol. 2004 Jul 15;22(14):2865-72 - PubMed
  7. Neurosurg Focus. 2007 Mar 15;22(3):E5 - PubMed
  8. Anticancer Res. 2007 Nov-Dec;27(6C):4255-7 - PubMed
  9. J Neurooncol. 2009 Jul;93(3):355-9 - PubMed
  10. J Neurooncol. 2010 Jun;98(2):249-52 - PubMed
  11. Thyroid. 2010 Jun;20(6):657-61 - PubMed
  12. Eur J Surg Oncol. 1990 Oct;16(5):448-50 - PubMed
  13. J Am Med Inform Assoc. 2012 Nov-Dec;19(6):965-72 - PubMed
  14. Thyroid. 2012 Aug;22(8):856-60 - PubMed
  15. Postgrad Med J. 1990 Feb;66(772):127-9 - PubMed
  16. Thyroid. 2014 Feb;24(2):270-6 - PubMed
  17. Lancet. 2014 Jul 26;384(9940):319-28 - PubMed
  18. N Engl J Med. 2015 Feb 12;372(7):621-30 - PubMed
  19. Thyroid. 2016 Jan;26(1):1-133 - PubMed
  20. Acta Neurochir (Wien). 2015 Dec;157(12):2185-94 - PubMed
  21. Eur J Endocrinol. 2016 Mar;174(3):373-80 - PubMed
  22. PLoS One. 2016 Apr 29;11(4):e0154739 - PubMed
  23. Front Surg. 2016 May 25;3:30 - PubMed
  24. Neuroimaging Clin N Am. 2016 Nov;26(4):601-620 - PubMed
  25. Mol Med Rep. 2017 Nov;16(5):7105-7111 - PubMed
  26. J Clin Oncol. 2018 Feb 10;36(5):483-491 - PubMed
  27. Cancer Discov. 2018 Jul;8(7):836-849 - PubMed
  28. J Nucl Med. 1976 Apr;17(4):307-9 - PubMed
  29. J Nucl Med. 1986 May;27(5):637-40 - PubMed
  30. Arch Intern Med. 1986 Oct;146(10):1985-7 - PubMed
  31. Am J Clin Oncol. 1982 Dec;5(6):649-55 - PubMed
  32. Clin Oncol (R Coll Radiol). 1996;8(5):327-30 - PubMed
  33. J Clin Endocrinol Metab. 1997 Nov;82(11):3637-42 - PubMed
  34. Thyroid. 1998 Apr;8(4):327-35 - PubMed

Publication Types